Iron supplementation aggravates periventricular cystic white matter lesions in newborn mice

European Journal of Paediatric Neurology

Volumn 2, Issue 6, 1998, Pages 313-318

  Dommergues, Marie Aliette ^a   Gallego, Jorge ^a   Evrard, Philippe ^a   Gressens, Pierre ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Iron supplementation; Neurological impairment in premature newborns; Periventricular leukomalacia

Indexed keywords

IRON;

ANIMAL EXPERIMENT; ARTICLE; DISEASE SEVERITY; ENCEPHALOMALACIA; IRON METABOLISM; IRON THERAPY; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032416757     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3798(98)80006-8     Document Type: Article

References (23)

1. Zupan V, Gonzalez P, Lacaze-Masmonteil T et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 1996; 38: 1061-1067.
2. Hagberg B, Olow I, Wendt LV. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year peiod 1987-90. Acta Paediatr 1996; 85: 954-960.
3. Evrard P, Marret S, Gressens P. Environmental determinants of brain development, with a special emphasis on the excitotoxic cascade at the consecutive developmental steps. In: Rating D (ed) Aktuelle Neuropädiatrie. Wehr: Ciba-Geigy Verlag, 1995: 22-33.
4. Volpe JJ. Neurology of the Newborn. Philadelphia: WB Saunders Co, 1995.
5. Murphy DJ, Sellers S, MacKenzie IZ et al. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very pretem singleton babies. Lancet 1995; 346: 1449-1454.
6. McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 1990; 15: 41-70.
7. Ikonomidou C, Mosinger JL, Salles KS et al. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-D-aspartate neurotoxicity. J Neurosci 1989; 9: 2809-2818.
8. Yoshioka A, Shimizu Y, Hirose G et al. Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J Neurochem 1995; 70: 2416-2423.
9. McDonald JW, Althomsons SP, Hyrc KL et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nature Med 1998; 4: 291-297.
10. Matute C, Sanchez-Gomez MV, Martinez-Milan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 1997; 94: 8830-8835.
11. Marret S, Mukendi R, Gadisseux JF et al. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 1995; 54: 358-370.
12. Gressens P, Marret S, Hill JM et al. Vasoactive intestinal peptide prevents excitotoxic hypoxic-like cell death in the murine developing brain. J Clin Invest 1997; 100: 390-397.
13. Bac P, Maurois P, Dupont C et al. Magnesium deficiency-dependent audiogenic seizures (MDDAS) in adult mice: a nutritional model for discriminatory screening of anticonvulsivant drugs and original assessment of neuroprotection properties. J Neurosci 1998; 18: 4363-4373.
14. Britton RS, Ramm GA, Olynyk J et al. Pathophysiology of iron toxicity. In: Hershko C, Konijn AM, Aisen P (eds). Progress in Iron Research. New York: Plenum Press, 1994: 239-253.
15. Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993; 16: 527-532.
16. Yonezawa M, Back SA, Gan X et al. Cystine deprivation induces oligodendroglial death: rescue by free radical scavengers and by a diffusible glial factor. J Neurochem 1996; 67: 566-573.
17. Marret S, Gressens P, Gadisseux JF, Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention. Dev Med Child Neurol 1995; 37: 473-484.
18. Meyer MP, Haworth C, Meyer JH, Commerford A. A comparaison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996; 129: 258-263.
19. Bechensteen AG, et al. Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity. Arch Dis Child 1993; 69: 19-23.
20. Roberts R, Sandra A, Siek GC et al. Studies of the mechanism of iron transport across the blood-brain barrier. Ann Neurol 1992; 32: S43-S50.
21. Risau W, Hallmann R, Albrecht U. Differentiation-dependent expression of proteins in brain endothelium during development of the blood-brain barrier. Dev Biol 1986; 117: 537-545.
22. Morishita E, Masuda S, Nagao M et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoierin prevents in vitro glutamate-induced neuronal death. Neurosci 1997; 76: 105-116.
23. Marret S, Bonnier C, Raymaekers JM et al. Systemic administration of anti-NOS and anti-glycine protects against excitotoxic lesions in the developing mouse brain. Pediat Res 1999 (in press).